Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 103-2314-B-182A-082-MY1-3 | Other Grant/Funding Number | MOST | |
| 106-2314-B-182A-113 | Other Grant/Funding Number | MOST | |
| CMRPD1G0611 | Other Grant/Funding Number | Chang Gung medical foundation | |
| CMRPD1H0661 | Other Grant/Funding Number | Chang Gung medical foundation | |
| CMRPG1J0061 | Other Grant/Funding Number | Chang Gung medical foundation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Science and Technology, Taiwan | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Two hundred HCC patients with partial hepatectomy were enrolled as a cohort for observational study. The inclusion criterion was intended curative hepatectomy for HCC patients by image analysis, and the exclusion criteria were unresectable disease, synchronous cancers, recurrent cancers, or distant metastasis. The study endpoint was 30 March 2019, and tumor staging was based on the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system for HCC
To determine the role of SOX4 in tumor progression in patients with HCC, we examined SOX4 expression through immunohistochemistry (IHC) staining of 200 formalin-fixed and paraffin-embedded (FFPE) HCC specimens . The SOX4 high group of patients was associated with positive etiology of hepatitis B virus (P = 0.044), tumor size >5 cm (P = 0.014), thrombus formation (P = 0.012), higher microvessel density (MVD) (P = 0.012) in tumor lesions, and distant metastasis (P <0.001).
Cox regression analysis showed that patients with elderly age (P <0.001), higher ⍺-fetal protein (AFP) (P = 0.045), presence of cirrhosis (P = 0.008), and SOX4 high in tumor specimen (P = 0.042) were independent risk factors . The SOX4 high group performed significantly worse regarding overall survival (OS) (P = 0.043) and disease-free survival (DFS) (P = 0.019) based on the Kaplan-Meier analysis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SOX4 high | Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group |
| |
| SOX4 low | Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| microvessel density | Other | the vessel numbers in high power field with Anti-CD31 staining in tumor specimen |
|
| Measure | Description | Time Frame |
|---|---|---|
| Disease free survival (DFS) | The length of time from curative hepatectomies and recurrence or mortality | a month |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | The length of time from curative hepatectomies and still alive | a month |
Not provided
Inclusion Criteria:
subjects with pathologic diagnosis of hepatocellular carcinoma and curative partial hepatectomies -
Exclusion Criteria:
history of different malignant disease, subject cannot be treated with curative surgery -
Not provided
Not provided
subjects with pathologic diagnosis of hepatocellular carcinoma
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000082644 | Microvascular Density |
| ID | Term |
|---|---|
| D002320 | Cardiovascular Physiological Phenomena |
| D002943 | Circulatory and Respiratory Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided